文献速递类风湿关节炎

乌帕替尼与阿达木单抗应答不足后互换治疗的疗效与安全性

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2020-11-04

SELECT-COMPARE 研究评估类风湿关节炎患者对乌帕替尼或阿达木单抗应答不足后立即互换治疗的疗效与安全性。结果显示互换后 3 和 6 个月疾病活动度改善,无清洗期未见新安全性信号。

要点

  • 应答不足后立即互换机制不同的药物可改善疾病活动度。
  • 互换后 6 个月部分患者达 CDAI 低疾病活动度。
  • 无清洗期互换未观察到新的安全性问题。

核心结论

  • 支持达标治疗策略,即初始应答不足者换用不同作用机制药物后可获改善。

研究设计与样本

  • SELECT-COMPARE 随机对照试验,患者随机分配至乌帕替尼 15 mg 每日一次(n=651)、安慰剂(n=651)或阿达木单抗 40 mg 隔周一次(n=327)。
  • 采用达标治疗设计,第 26 周前对压痛和肿胀关节数均未达至少 20% 改善者进行盲法拯救,第 26 周基于 CDAI>10 对不完全应答者拯救,无清洗期。

主要发现

  • 原随机分配至乌帕替尼和阿达木单抗的患者中分别有 39%(252/651)和 49%(159/327)被拯救至替代治疗。
  • 两个互换组及非应答者和不完全应答者中,拯救后 3 和 6 个月均观察到疾病活动度改善。
  • 互换至阿达木单抗和乌帕替尼的非应答者中分别有 36% 和 47% 达 CDAI 低疾病活动度,不完全应答者中分别有 45% 和 58% 达 CDAI 低疾病活动度(互换后 6 个月)。
  • 约 5% 的拯救患者在互换后 6 个月出现疾病活动度恶化。
  • 互换组间不良事件频率相似。

关键数值与推荐

  • 非应答者定义:第 26 周前压痛和肿胀关节数均未达至少 20% 改善。
  • 不完全应答者定义:第 26 周 CDAI>10。

临床怎么用

  • 对初始治疗应答不足的类风湿关节炎患者,可考虑立即换用不同作用机制的药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy. METHODS: SELECT-COMPARE randomised patients to upadacitinib 15 mg once daily (n=651), placebo (n=651) or adalimumab 40 mg every other week (n=327). A treat-to-target study design was implemented, with blinded rescue occurring prior to week 26 for patients who did not achieve at least 20% improvement in both tender and swollen joint counts ('non-responders') and at week 26 based on Clinical Disease Activity Index (CDAI) >10 ('incomplete-responders') without washout. RESULTS: A total of 39% (252/651) and 49% (159/327) of patients originally randomised to upadacitinib and adalimumab were rescued to the alternate therapy. In both switch groups (adalimumab to upadacitinib and vice versa) and in non-responders and incomplete-responders, improvements in disease activity were observed at 3 and 6 months following rescue. CDAI low disease activity was achieved by 36% and 47% of non-responders and 45% and 58% of incomplete-responders switched to adalimumab and upadacitinib, respectively, 6 months following switch. Overall, approximately 5% of rescued patients experienced worsening in disease activity at 6 months postswitch. The frequency of adverse events was similar between switch groups. CONCLUSIONS: These observations support a treat-to-target strategy, in which patients who fail to respond initially (or do not achieve sufficient response) are switched to a therapy with an alternate mechanism of action and experience improved outcomes. No new safety findings were observed despite immediate switch without washout.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fleischmann RM, Blanco R, Hall S, et al. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 33148701. doi:10.1136/annrheumdis-2020-218412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。